vimarsana.com
Home
Live Updates
Dr Chari on the Safety Profile of Talquetamab in Relapsed/Re
Dr Chari on the Safety Profile of Talquetamab in Relapsed/Re
Dr Chari on the Safety Profile of Talquetamab in Relapsed/Refractory Multiple Myeloma
Ajai Chari, MD, director, discusses the safety profile of talquetamab following the drug’s FDA approval for patients with relapsed/refractory multiple myeloma.
Related Keywords
New York ,
United States ,
,
Myeloma Program ,
Icahn School Of Medicine At Mount Sinai ,
Helen Diller Family Comprehensive Cancer Center ,
Ajai Chari ,
Multiple Myeloma Program ,
Diller Family Comprehensive Cancer Center ,
Icahn School ,
Mount Sinai ,
Ucsf Helen Diller Family Comprehensive Cancer Center ,
Onclive Tv ,
Multiple Myeloma ,